Identification and functional analysis of a second RBF-2 binding site within the HIV-1 promoter

Virology

Volumn 418, Issue 1, 2011, Pages 57-66

  Dahabieh, Matthew S ^a   Ooms, Marcel ^b   Malcolm, Tom ^a   Simon, Viviana ^b   Sadowski, Ivan ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

AP4; HIV 1; LTR; RBE1; RBE3; RBF 2; TFII I; Transcriptional regulation; USF

Indexed keywords

BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; BINDING PROTEIN; LUCIFERASE; RAS RESPONSIVE BINDING ELEMENT 1; RAS RESPONSIVE BINDING ELEMENT 3; RAS RESPONSIVE BINDING FACTOR 2; TRANSCRIPTION FACTOR II; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR 1; UPSTREAM STIMULATORY FACTOR 2;

ARTICLE; BINDING SITE; CELL NUCLEUS; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LEUKEMIA CELL LINE; LONG TERMINAL REPEAT; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; REPORTER GENE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRION;

BINDING SITES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENES, REPORTER; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; JURKAT CELLS; LUCIFERASES; MODELS, BIOLOGICAL; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECOMBINANT PROTEINS; TRANSCRIPTION FACTORS, TFII; UPSTREAM STIMULATORY FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052028580     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.07.002     Document Type: Article

References (51)

1. Alting-Mees M.A., Sorge J.A., Short J.M. pBluescriptII: multifunctional cloning and mapping vectors. Methods Enzymol. 1992, 216:483-495.
2. Bates D.L., Barthel K.K.B., Wu Y., Kalhor R., Stroud J.C., Giffin M.J., et al. Crystal structure of NFAT bound to the HIV-1 LTR tandem κB enhancer element. Structure 2008, 16:684-694.
3. Bell B., Sadowski I. Ras-responsiveness of the HIV-1 LTR requires RBF-1 and RBF-2 binding sites. Oncogene 1996, 13:2687-2697.
4. Bencini D.A., O'donovan G.A., Wild J.R. Rapid chemical degradation sequencing. Biotechniques 1984, 2:4-5.
5. Berkhout B., Silverman R.H., Jeang K.T. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 1989, 59:273-282.
6. Brooks D.G., Arlen P.A., Gao L., Kitchen C.M., Zack J.A. Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12955-12960.
7. Chen J., Malcolm T., Estable M.C., Roeder R.G., Sadowski I. TFII-I regulates induction of chromosomally integrated human immunodeficiency virus type 1 long terminal repeat in cooperation with USF. J. Virol. 2005, 79:4396-4406.
8. Coiras M., Lopez-Huertas M.R., Perez-Olmeda M., Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 2009, 7:798-812.
9. Colin L., Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009, 6:111.
10. Corre S., Galibert M.D. Upstream stimulating factors: highly versatile stress-responsive transcription factors. Pigment Cell Res. 2005, 18:337-348.
11. Cron R.Q., Bartz S.R., Clausell A., Bort S.J., Klebanoff S.J., Lewis D.B. NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells. Clin. Immunol. 2000, 94:179-191.
12. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74:8358-8367.
13. Durocher Y., Perret S., Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002, 30:E9.
14. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum. Gene Ther. 2005, 16:1241-1246.
15. Estable M.C., Bell B., Merzouki A., Montaner J.S., O'Shaughnessy M.V., Sadowski I.J. Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity. J. Virol. 1996, 70:4053-4062.
16. Estable M.C., Bell B., Hirst M., Sadowski I. Naturally occurring human immunodeficiency virus type 1 long terminal repeats have a frequently observed duplication that binds RBF-2 and represses transcription. J. Virol. 1998, 72:6465-6474.
17. Estable M.C., Hirst M., Bell B., O'Shaughnessy M.V., Sadowski I. Purification of RBF-2, a transcription factor with specificity for the most conserved cis-element of naturally occurring HIV-1 LTRs. J. Biomed. Sci. 1999, 6:320-332.
18. Ferre-D'Amare A.R., Pognonec P., Roeder R.G., Burley S.K. Structure and function of the b/HLH/Z domain of USF. EMBO J. 1994, 13:180-189.
19. Han Y., Wind-Rotolo M., Yang H.C., Siliciano J.D., Siliciano R.F. Experimental approaches to the study of HIV-1 latency. Nat. Rev. Microbiol. 2007, 5:95-106.
20. Harari A., Ooms M., Mulder L.C., Simon V. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 2009, 83:295-303.
21. Hu Y.F., Luscher B., Admon A., Mermod N., Tjian R. Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev. 1990, 4:1741-1752.
22. Imai K., Okamoto T. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J. Biol. Chem. 2006, 281:12495-12505.
23. Jeeninga R.E., Hoogenkamp M., Armand-Ugon M., de Baar M., Verhoef K., Berkhout B. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J. Virol. 2000, 74:3740-3751.
24. Kinoshita S., Su L., Amano M., Timmerman L.A., Kaneshima H., Nolan G.P. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 1997, 6:235-244.
25. Koken S.E.C., Van Wamel J.L.B., Goudsmit J., Berkhout B., Geelent J.L.M.C. Natural variants of the HIV-1 long terminal repeat: analysis of promoters with duplicated DNA regulatory motifs. Virology 1992, 191:968-972.
26. Lassen K., Han Y., Zhou Y., Siliciano J., Siliciano R.F. The multifactorial nature of HIV-1 latency. Trends Mol. Med. 2004, 10:525-531.
27. Li Y.C., Ross J., Scheppler J.A., Franza B.R. An in vitro transcription analysis of early responses of the human immunodeficiency virus type 1 long terminal repeat to different transcriptional activators. Mol. Cell. Biol. 1991, 11:1883-1893.
28. Malcolm T., Chen J., Chang C., Sadowski I. Induction of chromosomally integrated HIV-1 LTR requires RBF-2 (USF/TFII-I) and Ras/MAPK signaling. Virus Genes 2007, 35:215-223.
29. Malcolm T., Kam J., Pour P.S., Sadowski I. Specific interaction of TFII-I with an upstream element on the HIV-1 LTR regulates induction of latent provirus. FEBS Lett. 2008, 582:3903-3908.
30. Mermod N., Williams T.J., Tjian R. Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature 1988, 332:557-561.
31. Michael N.L., D'Arcy L., Ehrenberg P.K., Redfield R.R. Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and tat-induced transcriptional activities. J. Virol. 1994, 68:3163-3174.
32. Mok H.P., Lever A.M. Chromatin, gene silencing and HIV latency. Genome Biol. 2007, 8:228.
33. Ou S.H., Garcia-Martinez L.F., Paulssen E.J., Gaynor R.B. Role of flanking E box motifs in human immunodeficiency virus type 1 TATA element function. J. Virol. 1994, 68:7188-7199.
34. Pastier D., Lacorte J.M., Chambaz J., Cardot P., Ribeiro A. Two initiator-like elements are required for the combined activation of the human apolipoprotein C-III promoter by upstream stimulatory factor and hepatic nuclear factor-4. J. Biol. Chem. 2002, 277:15199-15206.
35. Peden K., Emerman M., Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 1991, 185:661-672.
36. Pereira L.A., Bentley K., Peeters A., Churchill M.J., Deacon N.J. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res. 2000, 28:663-668.
37. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
38. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
39. Robichaud G.A., Barbeau B., Fortin J.F., Rothstein D.M., Tremblay M.J. Nuclear factor of activated T cells is a driving force for preferential productive HIV-1 infection of CD45RO-expressing CD4+ T cells. J. Biol. Chem. 2002, 277:23733-23741.
40. Roy A.L. Signal-induced functions of the transcription factor TFII-I. Biochim. Biophys. Acta 2007, 1769:613-621.
41. Roy A.L., Meisterernst M., Pognonec P., Roeder R.G. Cooperative interaction of an initiator-binding transcription initiation factor and the helix-loop-helix activator USF. Nature 1991, 354:245-248.
42. Sadowski I., Mitchell D.A. TFII-I and USF (RBF-2) regulate Ras/MAPK-responsive HIV-1 transcription in T cells. Eur. J. Cancer 2005, 41:2528-2536.
43. Sadowski I., Lourenco P., Malcolm T. Factors controlling chromatin organization and nucleosome positioning for establishment and maintenance of HIV latency. Curr. HIV Res. 2008, 6:286-295.
44. Sirito M., Lin Q., Maity T., Sawadogo M. Ubiquitous expression of the 43- and 44-kDa forms of transcription factor USF in mammalian cells. Nucleic Acids Res. 1994, 22:427-433.
45. Smith S.D., Shatsky M., Cohen P.S., Warnke R., Link M.P., Glader B.E. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res. 1984, 44:5657-5660.
46. Takeuchi Y., McClure M.O., Pizzato M. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 2008, 82:12585-12588.
47. Trono D., Van Lint C., Rouzioux C., Verdin E., Barre-Sinoussi F., Chun T.W., et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010, 329:174-180.
48. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46:1896-1905.
49. Weiss A., Wiskocil R.L., Stobo J.D. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J. Immunol. 1984, 133:123-128.
50. Wen Y.D., Cress W.D., Roy A.L., Seto E. Histone deacetylase 3 binds to and regulates the multifunctional transcription factor TFII-I. J. Biol. Chem. 2003, 278:1841-1847.
51. Yang X.P., Freeman L.A., Knapper C.L., Amar M.J., Remaley A., Brewer H.B., et al. The E-box motif in the proximal ABCA1 promoter mediates transcriptional repression of the ABCA1 gene. J. Lipid Res. 2002, 43:297-306.